Archive | European Approval

Nivolumab Earns FDA Approval as Adjuvant Therapy for Melanoma Based on Checkmate-238 Trial

According to the National Cancer Institute, about 2.2% of people will be diagnosed with melanoma at a point in their lifetime.

Read the full story

Posted in Melanoma In The News, European Approval

Ipilimumab Approaches EU Approval for Pediatric Melanoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of ipilimumab (Yervoy) for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Read the full story

Posted in Melanoma In The News, European Approval

EMA’s CHMP Recommends Yervoy for Patients 12 and Older with Advanced Melanoma

Yervoy (ipilimumab) has received a positive review by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of unresectable or metastatic melanoma in patients age 12 and older.

Read the full story

Posted in Melanoma In The News, European Approval

Breakthrough drug which DOUBLES the survival time for people with deadly melanoma is approved for use on the NHS

A breakthrough drug which uses a man-made virus to treat advanced skin cancer has been approved for use on the NHS.

Read the full story

Posted in Melanoma In The News, European Approval

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories